Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers
Open Access
- 10 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12), e0243651
- https://doi.org/10.1371/journal.pone.0243651
Abstract
Systemic sclerosis is a disease where microcirculation damage is critical in their beginning and vascular complications have similar pathogenic findings. Digital ulcers are a frequent complication in systemic sclerosis patients and pulmonary hypertension is one of the leading causes of death. The use of bosentan has been shown to be useful for the treatment of pulmonary arterial hypertension and to prevent new digital ulcers. However, is unknown if bosentan can prevent pulmonary hypertension. Our objective was to determine if bosentan is useful to prevent pulmonary hypertension in SSc patients. A retrospective study in 237 systemic sclerosis patients with digital ulcers history treated or not with bosentan to prevent it was made. We analyzed the occurrence of pulmonary hypertension defined by an echocardiogram pulmonary arterial pressure > 40 mmHg in the entire cohort. Demographic, clinical, and treatment variables were recorded for all patients. Statistical significance was denoted by p values < 0.05. Fifty-nine patients were treated with bosentan a median of 34 months. 13.8% of treated patients had pulmonary hypertension vs 23.7% of untreated patients (p 0.13) during the follow up. In multivariate analysis patients not treated with bosentan had 3.9fold-increased risk of pulmonary hypertension compared with patients under bosentan treatment (p < 0.02). Moreover the percentage carbon monoxide diffusing capacity (DLCO) in bosentan treated patients did not decrease from baseline to the end of follow-up (61.8±14% vs 57±20.1%, p = 0.89). We concluded that Systemic sclerosis patients with digital ulcers treated with bosentan seems to have less risk to develop pulmonary hypertension and to stabilize DLCOKeywords
This publication has 44 references indexed in Scilit:
- Review: Defining a Unified Vascular Phenotype in Systemic SclerosisArthritis & Rheumatology, 2017
- Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosisClinical Rheumatology, 2013
- In systemic sclerosis patients, Bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertensionRheumatology, 2013
- Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern EraSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyArthritis Research & Therapy, 2013
- Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressureArthritis & Rheumatism, 2012
- Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic SclerosisThe Journal of Rheumatology, 2010
- Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsBritish Journal of Dermatology, 2009
- Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialThe Lancet, 2008
- Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.2007